540 related articles for article (PubMed ID: 23278368)
1. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
2. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
Tjwa ET; van Oord GW; Hegmans JP; Janssen HL; Woltman AM
J Hepatol; 2011 Feb; 54(2):209-18. PubMed ID: 21095036
[TBL] [Abstract][Full Text] [Related]
3. Effects of entecavir on peripheral blood lymphocyte profiles in chronic hepatitis B patients with suboptimal responses to adefovir.
Zhang L; Wang Q; Zhao P; Hu X; Jiang Y
Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):514-23. PubMed ID: 24773272
[TBL] [Abstract][Full Text] [Related]
4. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
5. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
6. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
Fung J; Lai CL; Young J; Wong DK; Yuen J; Seto WK; Yuen MF
Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
[TBL] [Abstract][Full Text] [Related]
7. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients.
You J; Sriplung H; Geater A; Chongsuvivatwong V; Zhuang L; Li YL; Lei H; Liu J; Chen HY; Tang BZ; Huang JH
BMC Infect Dis; 2008 Sep; 8():123. PubMed ID: 18803883
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
9. Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.
Bonorino P; Ramzan M; Camous X; Dufeu-Duchesne T; Thélu MA; Sturm N; Dariz A; Guillermet C; Pernollet M; Zarski JP; Marche PN; Leroy V; Jouvin-Marche E
J Hepatol; 2009 Sep; 51(3):458-67. PubMed ID: 19596474
[TBL] [Abstract][Full Text] [Related]
10. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
13. Changes in the balance between Treg and Th17 cells in patients with chronic hepatitis B.
Su ZJ; Yu XP; Guo RY; Ming DS; Huang LY; Su ML; Deng Y; Lin ZZ
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):437-44. PubMed ID: 23747030
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
[TBL] [Abstract][Full Text] [Related]
15. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
[TBL] [Abstract][Full Text] [Related]
16. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
17. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
18. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
19. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
[TBL] [Abstract][Full Text] [Related]
20. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection.
Fisicaro P; Valdatta C; Boni C; Massari M; Mori C; Zerbini A; Orlandini A; Sacchelli L; Missale G; Ferrari C
Gut; 2009 Jul; 58(7):974-82. PubMed ID: 19201769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
